{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:20:24Z","timestamp":1770333624552,"version":"3.49.0"},"reference-count":20,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":189,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Lab Physicians"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          BACKGROUND OR CONTEXT: Pituitary adenoma (PA) is the most common pathology of the pituitary gland. Pituitary tumors were historically considered benign, however, from recent advances in pathological and molecular analyses, numerous prognostic markers have been identified, allowing a better characterization of tumor behavior and prediction of response to treatment and recurrences.<\/jats:p><jats:p>\n          AIMS AND OBJECTIVES: Evaluation of the epidemiological occurrence of pituitary tumors in our center and prediction of the benign, aggressive, or malignant nature of the tumor with the help of immunohistochemical markers (IHC) Ki-67, P53, and O-6-methylguanine-DNA methyltransferase (MGMT) along with radiology.<\/jats:p><jats:p>\n          MATERIALS AND METHODS: A prospective study was done in 33 cases. Patients with clinically suspected pituitary tumors and related symptoms and signs are referred from the endocrine outpatient department and subsequently operated at the neurosurgery department were selected. We have studied the clinical features, radiology, histopathology, and IHC with the help of Ki-67, P53, and MGMT of PA over 2 years.<\/jats:p><jats:p>\n          RESULTS: We have 94% (31\/33) cases of PA among them 94% (29\/31) cases are macroadenoma. The IHC was conducted on 30 cases (excluding 1 case of pituitary apoplexy) where Ki-67, p53, and MGMT have been used for IHC in order to analyze the prognosis of the PA, irrespective of the immunological subtype of the PA. In our study, only 13% (4 patients) had MGMT score 0 and 2 patients, among these 4 patients having above cutoff level of Ki-67 and p53 value, considered as aggressive (in case of Ki-67 &gt;3% and &gt;50% in case of p53). When comparing MGMT expression with recurrence, a high degree of significance was found (Mann\u2013Whitney U-test, P = 0.0038). Most of the recurrent tumors (6\/9) had MGMT score 1 or below and most of the nonrecurring tumor had MGMT score 2 or above. When comparing MGMT expression with aggressiveness, a high degree of significance was found (Mann\u2013Whitney U-test, P &lt; 0.0001). Finally, combining the radiological Ki-67, p53, and MGMT values, two cases of aggressive adenoma have been seen in our study, the remaining being benign adenomas (WHO classification 2004). We did not encounter any case of pituitary carcinoma. MGMT did not show any significant correlation with radiological grading and histology.<\/jats:p><jats:p>\n          CONCLUSION: The benign, aggressive, or malignant nature of PA can be effectively predicted with the help of IHC, such as Ki-67, p53, and MGMT. This helps in better patient management and predicts recurrences and prognosis.<\/jats:p>","DOI":"10.4103\/jlp.jlp_76_19","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T05:45:55Z","timestamp":1576734355000},"page":"323-329","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors"],"prefix":"10.25259","volume":"11","author":[{"given":"Chhanda","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Pathology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratap","family":"Mondal","sequence":"additional","affiliation":[{"name":"Department of Pathology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhumita","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Department of Pathology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satinath","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipsita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Handral","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, IPGME and R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"key-10.4103\/0974-2727.273561-1","first-page":"163","volume-title":"Epidemiology of pituitary adenomas","author":"Gold","year":"1981","journal-title":"Epidemiol Rev"},{"key":"key-10.4103\/0974-2727.273561-2","unstructured":"Lopes MB. Tumors of the pituitary gland. In: Fletcher CD, editor. Diagnostic Histopathology of Tumors. 4th ed., Ch. 17. Philadelphia, PA, USA: Elsevier Saunders; 2013. p. 1146."},{"key":"key-10.4103\/0974-2727.273561-3","first-page":"172","volume-title":"Guidelines for the diagnosis and treatment of acromegaly: A Canadian perspective","author":"Patel","year":"2000","journal-title":"Clin Invest Med"},{"key":"key-10.4103\/0974-2727.273561-4","first-page":"87","volume-title":"Aggressive pituitary tumors","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"key-10.4103\/0974-2727.273561-5","unstructured":"Lloyd RV, Kovacs K, Young WF Jr., Farrell WE, Asa SL, Trouillas J, et al. Tumours of the pituitary. In: DeLellis Ronald A, Lloyd RV, Heitz Philipp U, Charis E, editors. WHO Classification of Tumours \u2013 Tumours of Endocrine Organs. 3rd ed. France, Lyon: IARC Press; 2004. p. 12."},{"key":"key-10.4103\/0974-2727.273561-6","first-page":"219","volume-title":"MGMT promoter hypermethylation in a series of 104 glioblastomas","author":"Mellai","year":"2009","journal-title":"Cancer Genomics Proteomics"},{"key":"key-10.4103\/0974-2727.273561-7","first-page":"502","volume-title":"Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: Correlations with clinical behaviour and follow-up results","author":"Hadzhiyanev","year":"2014","journal-title":"Biotechnol Biotechnol Equip"},{"key":"key-10.4103\/0974-2727.273561-8","first-page":"67","volume-title":"The trends in incidence of primary brain tumors in the population of Rochester, Minnesota","author":"Radhakrishnan","year":"1995","journal-title":"Ann Neurol"},{"key":"key-10.4103\/0974-2727.273561-9","first-page":"203","volume-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"key-10.4103\/0974-2727.273561-10","first-page":"72","volume-title":"Non-functioning pituitary adenoma: Immunohistochemical analysis of 85 cases","author":"Mahta","year":"2007","journal-title":"Folia Neuropathol"},{"key":"key-10.4103\/0974-2727.273561-11","first-page":"418","volume-title":"A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience","author":"Rishi","year":"2010","journal-title":"Neurol India","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3886","issn-type":"print"},{"key":"key-10.4103\/0974-2727.273561-12","doi-asserted-by":"crossref","unstructured":"Kleinschmidt-DeMasters BK. Pituitary gland. In: Rosai J, editor. Rosai and Ackerman's Surgical Pathology. 10th ed., Ch. 29. Milan, Italy: Elsevier Inc.; 2011. p. 2441-66.","DOI":"10.1016\/B978-0-323-06969-4.00017-9"},{"key":"key-10.4103\/0974-2727.273561-13","first-page":"202","volume-title":"Pituitary adenomas in pediatric patients: Are they more invasive?","author":"Kanter","year":"1985","journal-title":"Pediatr Neurosci"},{"key":"key-10.4103\/0974-2727.273561-14","first-page":"495","volume-title":"Pathology of the human pituitary adenomas","author":"Osamura","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"key-10.4103\/0974-2727.273561-15","doi-asserted-by":"crossref","unstructured":"Ortiz-Plata A, Tena-Suck ML, P\u00e9rez-Neri I, Rembao-Boj\u00f3rquez D, Fern\u00e1ndez A. Pituitary Adenomas \u2013 Clinico-Pathological, Immunohistochemical and Ultrastructural Study. Adenomas P, Movaghar VR, Ed. 6, InTech. Chapter 4, Rijeka, Croatia 2012.","DOI":"10.5772\/34040"},{"key":"key-10.4103\/0974-2727.273561-16","first-page":"19674","volume-title":"O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis","author":"Dai","year":"2017","journal-title":"Oncotarget"},{"key":"key-10.4103\/0974-2727.273561-17","first-page":"99","volume-title":"Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody","author":"Thapar","year":"1996","journal-title":"Neurosurgery"},{"key":"key-10.4103\/0974-2727.273561-18","first-page":"429","volume-title":"Ki-67 in pituitary neoplasms: A review \u2013 Part I","author":"Salehi","year":"2009","journal-title":"Neurosurgery"},{"key":"key-10.4103\/0974-2727.273561-19","first-page":"765","volume-title":"P53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions","author":"Thapar","year":"1996","journal-title":"Neurosurgery"},{"key":"key-10.4103\/0974-2727.273561-20","unstructured":"Lloyd RV, Osamura Robert Y. Tumours of the pituitary. In: Kloppel G, Rosai J, editors. WHO Classification of Tumours \u2013 Tumours of Endocrine Organs. 4th ed. France, Lyon: IARC Press; 2017. p. 18."}],"container-title":["Journal of Laboratory Physicians"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/JLP.JLP_76_19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:16:31Z","timestamp":1703405791000},"score":1,"resource":{"primary":{"URL":"https:\/\/jlabphy.org\/evaluation-of-prognostic-utility-of-ki-67-p53-and-o-6-methylguanine-dna-methyltransferase-expression-in-pituitary-tumors\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":20,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.4103\/jlp.jlp_76_19","relation":{},"ISSN":["0974-2727","0974-7826"],"issn-type":[{"value":"0974-2727","type":"print"},{"value":"0974-7826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}